Samsung BioLogics Co (XKRX:207940) FCF Margin % : -14.57% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Samsung BioLogics Co's Free Cash Flow for the three months ended in Dec. 2024 was ₩-183,004 Mil. Samsung BioLogics Co's Revenue for the three months ended in Dec. 2024 was ₩1,256,439 Mil. Therefore, Samsung BioLogics Co's FCF Margin % for the quarter that ended in Dec. 2024 was -14.57%.

As of today, Samsung BioLogics Co's current FCF Yield % is 0.38%.

The historical rank and industry rank for Samsung BioLogics Co's FCF Margin % or its related term are showing as below:

XKRX:207940' s FCF Margin % Range Over the Past 10 Years
Min: -721.41 Med: -13.13 Max: 15.18
Current: 6.2

During the past 11 years, the highest FCF Margin % of Samsung BioLogics Co was 15.18%. The lowest was -721.41%. And the median was -13.13%.

XKRX:207940's FCF Margin % is ranked better than
81.97% of 1004 companies
in the Biotechnology industry
Industry Median: -126.31 vs XKRX:207940: 6.20

Samsung BioLogics Co FCF Margin % Historical Data

The historical data trend for Samsung BioLogics Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co FCF Margin % Chart

Samsung BioLogics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

4.60

2.13

-1.87

15.18

6.20

Samsung BioLogics Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															49.73	18.70	10.18	14.31	-14.57

Competitive Comparison of Samsung BioLogics Co's FCF Margin %

For the Biotechnology subindustry, Samsung BioLogics Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Samsung BioLogics Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Samsung BioLogics Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Samsung BioLogics Co's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	281729.869	/	4547322.176
	=	6.20 %

Samsung BioLogics Co's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-183003.631	/	1256439.192
	=	-14.57 %

Samsung BioLogics Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR

Website

https://www.samsungbiologics.com

Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines